06/07/23 4:10 PMNasdaq : DCTH low floatDelcath Systems Announces Sandra Pennell as Senior Vice President of FinanceDelcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce that the Company has appointed Sandra Pennell as its new Senior Vice President of Finance. Pennell joins the Company with over twenty-years of experience in a variety of...RHEA-AIneutral
05/12/23 8:00 AMNasdaq : DCTH earningslow floatDelcath Systems Provides Business Update and Reports Preliminary First Quarter 2023 Financial ResultsDelcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and certain preliminary financial results for the first quarter ended March 31, 2023.. Received an acknowledgement of Class 2 NDA resubmission from the U.S....RHEA-AIneutral
05/09/23 9:00 AMNasdaq : DCTH conferenceslow floatDelcath Systems to Participate in the Lytham Partners Spring 2023 Investor ConferenceDelcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will be participating in the Lytham Partners Spring 2023 Investor Conference taking place virtually on Thursday, May 18, 2023.. Delcath CEO Gerard Michel will be participating on a panel titled...RHEA-AIneutral
05/03/23 8:30 AMNasdaq : DCTH conferenceslow floatDelcath Systems to Host First Quarter 2023 ResultsDelcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 12, 2023, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2023.. In the United States, the PHP system is being...RHEA-AIneutral
04/03/23 4:30 PMNasdaq : DCTH low floatDelcath Systems Announces Resumption of Interest-Only Period for Company's Debt FacilityDelcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced it reached an agreement to amend its existing loan agreement with Avenue Venture Opportunities Fund, L.P.. The I/O period may be extended at Delcath's option to December 31, 2023 if, by September 30, 2023, Delcath has...RHEA-AIvery positive
03/29/23 9:41 PMNasdaq : DCTH low floatDelcath Systems Announces Closing of Private Placement of up to $85 MillionDelcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announces that it has closed its previously announced private placement, for gross proceeds of approximately $25.0 million from the issuance and sale of shares of the Company's common stock and shares of its Series F...RHEA-AIneutral
03/27/23 8:20 AMNasdaq : DCTH low floatDelcath Systems Reports Fourth Quarter and Full Year 2022 Results and Provides Business UpdateDelcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2022. During and since the fourth quarter, Delcath Systems, Inc.:. Received an acceptance of the NDA resubmission...RHEA-AIneutral
03/27/23 8:15 AMNasdaq : DCTH low floatDelcath Systems Announces up to $85 Million FinancingDelcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that the Company has signed securities purchase agreements with certain healthcare-focused institutional investors that will provide up to $85 million in gross proceeds to Delcath through a private...RHEA-AIneutral
03/27/23 8:10 AMNasdaq : DCTH low floatDelcath Systems, Inc. Announces FDA Acceptance of New Drug Application Resubmission of Hepzato Kit with a PDUFA Date of August 14, 2023Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that the US Food and Drug Administration has accepted Delcath Systems, Inc.' s new drug application resubmission for HEPZATO™ Kit seeking approval for the treatment of patients with unresectable hepatic-dominant...RHEA-AIneutral
02/16/23 8:30 AMNasdaq : DCTH managementlow floatDelcath Announces Rotation of the Board of Directors Chairmanship; John R. Sylvester Appointed New Chairman as Company Prepares for US Commercial LaunchDelcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that its Board of Directors has voted to appoint John R. Sylvester as Delcath's new Chairman. Mr. Sylvester has served as a Director of Delcath since July 2019 and has extensive experience building interventional...RHEA-AIvery positive